<DOC>
	<DOCNO>NCT00073320</DOCNO>
	<brief_summary>The purpose study compare pharmacokinetic parameter ( blood concentration ) i.m . paliperidone palmitate administration 2 different injection site ( deltoid gluteal ) .</brief_summary>
	<brief_title>Intramuscular Injections Paliperidone Palmitate Arm Buttock Subjects With Schizophrenia</brief_title>
	<detailed_description>An i.m . paliperidone palmitate long-acting formulation development aim provide sustain stable level paliperidone treatment cycle . The goal study determine similarity pharmacokinetic ( blood level ) safety profile 2 intramuscular injection paliperidone palmitate arm ( deltoid muscle ) buttock ( gluteal muscle ) , dose range cover later Phase 3 trial ( 25 - 150 mg eq. ) . This repeated-dose , open-label , parallel group study patient schizophrenia . The study consist 5-day screening period , 3-day tolerability period , 14-day washout period , 64-day treatment period . As paliperidone active metabolite risperidone , patient expose oral risperidone screen period confirm develop allergic reaction risperidone , help investigator assign patient 1 2 treatment dos . There washout least 2 week last oral risperidone intake patient receive first injection paliperidone palmitate . Each treatment group ( arm buttock injection ) receive 2 consecutive i.m . injection long-acting formulation paliperidone palmitate one-week interval . Whole blood sample collect determination paliperidone palmitate paliperidone concentration plasma . Whole blood sample obtain venipuncture ( needle stick ) immediately ( pre-dose ) 4 , 8 , 12 , 24 , 48 , 72 , 96 hour 1st 2nd injection paliperidone palmitate . Following collection 96-hour blood sample 2nd injection , additional sample collect every 3 7 day end 64-day treatment period . Safety assess throughout study monitor adverse event ; change clinical laboratory result ; tardive dyskinesia rat use Abnormal Involuntary Movement Scale ( AIMS ) , akathisia rat accord Barnes Akathisia Rating Scale ( BARS ) , extrapyramidal symptom evaluate use Simpson-Angus Rating Scale ( SAS ) ; physical examination ; electrocardiogram ( ECGs ) ; patient evaluation injection site . Paliperidone palmitate ( 25 150 mg eq . ) , 2 i.m . dos administer 1-week interval . Depending randomized treatment group , patient receive 3 dos oral risperidone : either 1 mg daily 3 day 2 mg 1st day , 4 mg 2nd day , 6 mg 3rd day .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Patients diagnosis schizophrenia clinically stable change current antipsychotic medication meet PANSS score criterion body mass index ( BMI ) 15 35 kilogram ( kg ) /meter ( ) 2 . Patients DSMIV diagnosis alcohol substance dependence , exception nicotine caffeine dependence involuntarilycommitted moderately severe severe EPS symptom history malignant neuroleptic syndrome current suicidal ideation demonstrate violence current presence significant unstable medication condition treatment protocol disallow therapy clinically significant result screen laboratory ECG .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Paliperidone palmitate</keyword>
	<keyword>R092670</keyword>
	<keyword>antipsychotic</keyword>
</DOC>